Filing Flows › Comparisons › BMRN vs PRGO
BioMarin Pharmaceutical vs Perrigo: BMRN and PRGO compared
BioMarin Pharmaceutical is the larger company: $1.0B of revenue in its latest quarter (Q3 2026) against $989M for Perrigo (Q3 2026). BioMarin Pharmaceutical is growing faster (+32% against -5% a year earlier). Perrigo is more profitable, with an operating margin of 2.3% against -8.0%.
Where the money goes: BMRN and PRGO
BioMarin Pharmaceutical (BMRN) · Q3 2026
BioMarin Pharmaceutical, Q3 2026: revenue $1.0B (+32% year over year), operating margin -8.0%, net loss $123M, operating cash flow $188M. The chart follows the revenue to costs, profit and cash.
Perrigo (PRGO) · Q3 2026
Perrigo, Q3 2026: revenue $989M (-5% year over year), operating margin 2.3%, net loss $27.5M, operating cash flow $96.2M. The chart follows the revenue to costs, profit and cash.
| BioMarin Pharmaceutical (BMRN) | Perrigo (PRGO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $1.0B | $989M |
| Revenue growth, Y/Y | +32% | -5% |
| Operating margin | -8.0% | 2.3% |
| Net earnings | −$123M | −$27.5M |
| Net margin | -12.0% | -2.8% |
| Operating cash flow | $188M | $96.2M |
| Free cash flow | $160M | $78.7M |
| Market value | $10.8B | $2.2B |
| Analysts’ mean target | $90.78 | $18.00 |
Where the revenue comes from
BioMarin Pharmaceutical
- Net product revenues: $1.0B (99%)
- Royalty and other revenues: $11.6M (1%)
Questions
Which is bigger, BioMarin Pharmaceutical or Perrigo?
BioMarin Pharmaceutical is the larger company: $1.0B of revenue in its latest quarter (Q3 2026) against $989M for Perrigo (Q3 2026).
Is BioMarin Pharmaceutical or Perrigo growing faster?
BioMarin Pharmaceutical is growing faster (+32% against -5% a year earlier).
Which is more profitable, BioMarin Pharmaceutical or Perrigo?
Perrigo is more profitable, with an operating margin of 2.3% against -8.0%.
More: BioMarin Pharmaceutical earnings · how BioMarin Pharmaceutical makes money · Perrigo earnings · how Perrigo makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.